10-Q quarterly report · filed Nov 9, 2026

Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 10-Q Quarterly Report

Short answer

Atea Pharmaceuticals, Inc. (AVIR) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$32M
+23.5% YoY · +2.3% QoQ
EPS (diluted)
−$0.39
+25.0% YoY · +7.1% QoQ

Source: XBRL data from the Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 10-Q on SEC EDGAR. USD.

Atea Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved or product sales generated
  • Operating loss $34.0M vs $45.6M YoY, operating margin not applicable
  • HCV R&D $17.4M vs $30.2M, strongest program; HEV R&D $2.7M vs $0
  • Cash and investments $191.2M; nine-month operating cash use $112.3M vs $103.8M
  • C-FORWARD results expected Q1 2027, FDA NDA submission targeted Q2 2027; funding expected into mid-2028

Risk Factors

  • New debt facility: November 2026 Hercules agreement adds $65.0 million funded debt, floating-rate interest, and $200.0 million total commitments
  • Liquidity risk: $105.0 million of undrawn capacity requires milestones, while $30.0 million remains at lenders’ discretion
  • Regulatory pricing risk: September 2026 Globe regulation may require Medicare Part B rebates based on most-favored-nation pricing
  • Clinical risk: C-FORWARD Phase 3 results remain critical, with topline results anticipated in first-quarter 2027
  • Financial condition: Nine-month 2026 net loss reached $110.5 million, with accumulated deficit of $633.1 million

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Atea Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.